Ticker

Aura Biosciences, Inc. (AURA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, AURA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

The mean of analysts' price targets for Aura Biosciences (AURA) points to a 201.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a…

Shares of Aura Biosciences, Inc. (NASDAQ: AURA - Get Free Report) have been assigned an average rating of "Hold" from the five brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to